Dori Pelled
Chief Operating Officer at Imel Biotherapeutics, Inc.
Profile
Dori Pelled is currently the Chief Operating Officer at Imel Biotherapeutics, Inc. He previously worked as the CTO & Director-Clinical Research at Enzymotec Ltd.
and as the Vice President-Operations at Eloxx Pharmaceuticals, Inc. He received his undergraduate and graduate degrees from Tel-Aviv University and his doctorate from Weizmann Institute of Science.
Dori Pelled active positions
| Companies | Position | Start |
|---|---|---|
Imel Biotherapeutics, Inc.
 Imel Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Imel Biotherapeutics, Inc. develops treatment for mitochondrial disease. The company was founded on February 21, 2019 and is headquartered in United States. | Chief Operating Officer | 2019-02-28 |
Former positions of Dori Pelled
| Companies | Position | End |
|---|---|---|
| ELOXX PHARMACEUTICALS, INC. | Chief Operating Officer | 2018-06-24 |
| ENZYMOTEC LTD. | Chief Tech/Sci/R&D Officer | - |
Training of Dori Pelled
| Tel-Aviv University | Graduate Degree |
| Weizmann Institute of Science | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ELOXX PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Enzymotec Ltd.
 Enzymotec Ltd. BiotechnologyHealth Technology Enzymotec Ltd. develops and manufactures bio functional ingredients for health needs. The company was founded on March 8, 1998 and is headquartered in Migdal HaEmeq, Israel. | Health Technology |
Imel Biotherapeutics, Inc.
Imel Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Imel Biotherapeutics, Inc. develops treatment for mitochondrial disease. The company was founded on February 21, 2019 and is headquartered in United States. | Commercial Services |
- Stock Market
- Insiders
- Dori Pelled
